ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2995

Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies

Maria C Fonseca1, Sandra Guerra1, Edward Stern1,2, Svetlana I. Nihtyanova1, David Abraham3, Aine Burns2, Mark Harber2 and Christopher P. Denton4, 1Rheumatology, UCL Division of Medicine, London, United Kingdom, 2Nephrology, Royal Free Hospital, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, genetics, Renal disease, scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Scleroderma renal crisis (SRC) is a severe complication
of systemic sclerosis (SSc). Most SSc cases demonstrate a disease-specific
antinuclear antibody including anti-RNA polymerase III (ARA), anti-fibrillarin (AFA),
anti-topisomerase-1 (ATA) or anticentromere (ACA). ARA defines a distinct sub-phenotype characterised by diffuse skin
disease and risk of complications including SRC and pulmonary arterial
hypertension. We used the strong association between ARA and SRC and the predominant
occurrence of SRC early in disease to develop an extreme phenotype strategy for
defining genetic factors in susceptibility to renal crisis.

Methods:
First we analysed SRC in a well characterised group of SSc cases followed at
our centre (n=415). Informed by this, 50 patients with confirmed SRC and ARA+
and another 50 SSc ARA+ that had never developed SRC were identified from our
larger SSc cohort. These cases, all with Northern European ancestry, were
genotyped across approximately one million SNPs using the Illumina Human
Omni-express bead array chip. All data underwent quality control checks for
Hardy-Weinberg equilibrium and genotyping rate in PLINK (HWE p < 0.001, and
genotyping rate > 90%). After filtering of SNPs, a logistic regression was
performed in PLINK comparing patients with or without SRC to determine the
genetic signature difference between these two groups of patients.

Results:
Initial analysis confirmed a strong association between ARA and SRC with 30%
ARA+ SSc developing SRC compared with 7% AFA, 4% ATA and 1% ACA (p < 0.001).
Moreover in ARA+ cases almost all SRC occurred within 18 months of disease
onset, and SRC after 5 years of follow up was very rare. Thus we could define a
group with SRC and another at very low risk. This dichotomy formed the basis of
our genetic analysis comparing ARA+ patients with SRC history (Group A) to the
control group, who had been followed for > 60 months without SRC (Group B).
We performed GWAS analysis on these two groups. Quality control checks removed
2309 SNPs for missingness (GENO > 0.1) and 77122 failed MAF filters (MAF
< 0.01). In total 641,489 SNPs were analysed. The logistic regression
analysis identified a number of SRC associated SNPs within genes and gene
regions. Top associations were found in the complement region (P= 1.66×10-5),
and in other genes including EPHA5 (P= 1.87×10-5), GRIA3 (P= 2.16×10-5), HECW2
(P= 2.71×10-5) and CTNND2 (P= 2.92×10-5).

Conclusion:
We present a novel study using extreme phenotypes of ARA+ SSc to identify
genetic association of SRC in cases that are serologically and clinically
otherwise homogeneous. We identified genes including Caterin
cadherin-associated protein delta 2 (CTNND2) which is known to regulate
adhesion molecules relevant to fibrosis. Genes identified from this analysis
may have general relevance to SSc vasculopathy or other forms of hypertensive
thromobotic microangiopathy. Additional functional and genetic replication
studies are needed.


Disclosure: M. C. Fonseca, None; S. Guerra, None; E. Stern, None; S. I. Nihtyanova, None; D. Abraham, None; A. Burns, None; M. Harber, None; C. P. Denton, GlaxoSmithKline, 2,Actelion Pharmaceuticals US, 5,GlaxoSmithKline, 5,Serono, 5,Inventiva, 5,CSL Behring, 2,Bayer, 5.

To cite this abstract in AMA style:

Fonseca MC, Guerra S, Stern E, Nihtyanova SI, Abraham D, Burns A, Harber M, Denton CP. Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/genome-wide-analysis-in-scleroderma-renal-crisis-defining-genetic-risk-in-patients-with-rna-polymerase-iii-auto-antibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-analysis-in-scleroderma-renal-crisis-defining-genetic-risk-in-patients-with-rna-polymerase-iii-auto-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology